Trials / Sponsors / Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc.
Industry · 4 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Terminated | A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancer | Phase 1 | 2024-02-28 |
| Terminated | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ R Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma | Phase 1 | 2021-10-08 |
| Terminated | An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymp Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma | Phase 2 | 2021-05-28 |
| Completed | Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancie Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders | Phase 1 / Phase 2 | 2018-03-29 |